Navigation Links
Hormone therapy for prostate cancer does not appear to increase cardiac deaths

Treating prostate cancer patients with drugs that block hormonal activity does not appear to increase the risk of death from cardiovascular disease, according to a study led by Massachusetts General Hospital (MGH) researchers. While a 2006 report from members of the same study team found that treatment with gonadotropin-releasing hormone (GnRH) agonists increased the risk of diabetes and heart disease, the current study is the first to examine whether treatment actually increased heart-disease-related deaths. In their Journal of Clinical Oncology report, which has been released online, the researchers note that GnRH agonist treatment has a number of adverse side effects, which should be kept in mind when determining treatment strategies.

"Hormonal therapy for prostate cancer has become routine for many patients, so it's even more important to understand the potential adverse effects of treatment," says lead author Jason Efstathiou, MD, PhD, of the MGH Cancer Center. "Given recent concerns about the safety and impact on cardiac health of hormonal therapies particularly GnRN agonists our study is quite timely."

Since the male hormones called androgens can accelerate the development of prostate cancer, reducing their activity is a standard part of treating the disease. Most commonly this is done with GnRH agonists that block the production of all sex hormones. GnRH agonist therapy is routinely administered to men whose cancer has spread beyond the prostate gland, and its use in patients whose tumors appear confined to the prostate is becoming more common. It is estimated that one-third of the two million prostate cancer survivors in the U.S. are currently receiving this therapy, making understanding the potential adverse effects of treatment particularly important.

The earlier report from a Harvard Medical School team including Matthew Smith, MD, PhD, of the MGH Cancer Center, who is corresponding author of the current study found that men with localized prostate cancer who received GnRH agonist therapy had a greater risk of developing diabetes or cardiovascular disease than patients not receiving hormonal treatment. To specifically investigate the relationship between GnRH agonist therapy and death from cardiovascular disease, the current study analyzed data from a 1987-92 clinical trial in which almost 1,000 patients were treated for locally advanced prostate cancer with either the GnRH agonist goserelin plus radiation therapy or radiation therapy alone.

During the decade following completion of the clinical trial, more than half the participants died from various causes. Of the 574 deaths, 117 were from cardiovascular disease, but whether or not patients had received the GnRH agonist apparently had no effect on the risk of cardiovascular death. Instead, it was established cardiac risk factors including heart disease or diabetes that existed prior to GnRH agonist treatment that appeared to increase the risk of dying from cardiovascular disease.

"The absence of an increase in cardiovascular mortality does not exclude the possibility that GnRH agonists increase non-cancer deaths through other mechanisms," Efstathiou stresses. "In addition to the increased risk for diabetes identified in the 2006 study, we know they can raise the risk of fractures and anemia both of which can reduce survival and can have adverse effects on weight gain, cholesterol levels, mood and sexual function.

"While our study supports the continued use of GnRH agonists in situations where the benefit for cancer control has been established typically the treatment of advanced or more aggressive prostate cancer clinicians should keep in mind the risks of diabetes and cardiovascular disease and help their patients adopt strategies to reduce those risks," he adds. "Further studies are needed to evaluate potential risks for men with earlier stage prostate cancer, for whom the role of GnRH agonists is not as well defined, and treatment decisions need to carefully weigh potential risks and benefits." Efstathiou is an instructor in Radiation Oncology at Harvard Medical School.


Contact: Katie Marquedant
Massachusetts General Hospital

Related medicine news :

1. Drop in breast cancer incidence linked to hormone use, not mammograms
2. Researchers develop long-lasting growth hormone
3. One of the Largest Post-WHI Physician Surveys Shows More Education is Needed: Patient Misinformation About Hormone Therapy Remains High
4. Less than one-third of women aware of landmark hormone therapy study, Stanford researcher finds
5. Most Women Unaware of Hormone Replacement Study
6. Survival data presented from phase II study of hormone-resistant prostate cancer patients
7. Hormone May Play Key Part in Creating Memories
8. Hormone Therapy for Prostate Cancer Linked to Heart Risks
9. Wyeth to Appeal Nevada Hormone Therapy Trial Verdict
10. New data on hormone therapy must lead to re-evaluation of official guidelines
11. From Hot Flashes to Breast Cancer: ZRT Labs Hormone Testing Catches On As Women Consider Safer, More Natural Options.
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Today, Mothers Against Drunk Driving ... dropped below 10,000 for the first time since 2011. In 2014, there were 9,967 ... data released by the National Highway Traffic Safety Administration (NHTSA), 32,675 people were killed ...
(Date:11/25/2015)... ... November 25, 2015 , ... "When I underwent breast reconstruction ... incredibly uncomfortable," said an inventor from Bronx, N.Y. "In order to meet my ... RECOVERY BRA for added comfort and support. The bra is easier to put ...
(Date:11/25/2015)... ... 25, 2015 , ... Many people know of the common symptoms of low ... dry skin. But many people who find their cholesterol levels and weight are creeping ... thyroid, especially if they don’t have any of the other symptoms. , Thyroid hormone ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something ... winners of the Create Real Impact awards. California Casualty is proud to ... the tide of distracted and reckless driving, the number one killer of young drivers. ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... certified to offer their patients the many benefits of the revolutionary BIOLASE WaterLase ... sharp cutting and scraping tools traditionally used by a dentist in Gettysburg, ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... 24, 2015   HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... Executive Officer Doug Godshall is scheduled to ... Healthcare Conference on December 1, 2015 at 3:00 p.m. ... New York . ...
(Date:11/24/2015)... LAUSANNE and BERN, Switzerland ... SA, the ARTORG Center for Biomedical Engineering Research of ... and the Division of Endocrinology, Diabetes and Clinical Nutrition ... announce the start of an exclusive collaboration to develop ... control algorithm for the personalised delivery of insulin for ...
(Date:11/24/2015)... 2015 F1000Workspace - a research ... it was launched just six months ago. --> ... platform for scientists - since it was launched just six ... loaded on to F1000Workspace - a research collaboration, ... was launched just six months ago. --> ...
Breaking Medicine Technology: